Fortress Biotech, Inc. (FBIO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 62.02M USD | Liabilities, Current |
| Cash and equivalents | 196.58M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 36.25M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 8.16M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $62.02M | $196.58M | (m) | $36.25M | $8.16M | (m) |
| 2026-03-31 | (m) | $103.39M | $255.84M | (m) | $24.99M | $9.29M | (m) |
| 2025-12-31 | (m) | $49.74M | $79.38M | (m) | $29.78M | $9.62M | (m) |
| 2025-09-30 | (m) | $54.07M | $86.22M | (m) | $17.98M | $11.82M | (m) |
| 2025-06-30 | (m) | $57.52M | $74.39M | (m) | $15.64M | $12.85M | (m) |
| 2025-03-31 | (m) | $73.67M | $91.34M | (m) | $18.02M | $12.50M | (m) |
| 2024-12-31 | (m) | $71.40M | $57.26M | (m) | $10.23M | $14.43M | (m) |
| 2024-09-30 | (m) | $70.31M | $58.85M | (m) | $10.67M | $11.79M | (m) |
| 2024-06-30 | (m) | $75.54M | $76.20M | (m) | $10.46M | $9.69M | (m) |
| 2024-03-31 | (m) | $87.70M | $83.77M | (m) | $9.80M | $10.58M | (m) |
| 2023-12-31 | (m) | $84.91M | $80.93M | (m) | $15.22M | $10.21M | (m) |
| 2023-09-30 | (m) | $97.35M | $72.31M | (m) | $7.99M | $11.02M | (m) |
| 2023-06-30 | (m) | $128.58M | $78.02M | (m) | $16.74M | $12.17M | (m) |
| 2023-03-31 | (m) | $129.47M | $152.48M | (m) | $27.62M | $13.28M | (m) |
| 2022-12-31 | (m) | $127.72M | $178.27M | (m) | $28.21M | $14.16M | (m) |
| 2022-09-30 | (m) | $106.30M | $208.35M | (m) | $28.53M | $15.23M | (m) |
| 2022-06-30 | (m) | $104.92M | $248.77M | (m) | $28.67M | $16.05M | (m) |
| 2022-03-31 | (m) | $103.14M | $287.51M | (m) | $31.18M | $16.14M | (m) |
| 2021-12-31 | (m) | $101.04M | $305.74M | (m) | $23.11M | $9.86M | (m) |
| 2021-09-30 | (m) | $103.21M | $252.72M | (m) | $31.74M | $11.61M | (m) |
| 2021-06-30 | (m) | $70.60M | $274.99M | (m) | $26.19M | $14.31M | (m) |
| 2021-03-31 | (m) | $53.82M | $289.90M | (m) | $19.44M | $2.29M | (m) |
| 2020-12-31 | (m) | $47.96M | $233.35M | (m) | $19.35M | $1.40M | (m) |
| 2020-09-30 | (m) | $37.28M | $218.39M | (m) | $15.65M | $1.05M | (m) |
| 2020-06-30 | (m) | $56.97M | $183.28M | (m) | $11.17M | $1.21M | (m) |
| 2020-03-31 | (m) | $51.73M | $135.94M | (m) | $15.81M | $769.00K | (m) |
| 2019-12-31 | (m) | $45.62M | $136.86M | (m) | $13.54M | $857.00K | (m) |
| 2019-09-30 | (m) | $46.85M | $134.94M | (m) | $5.14M | $941.00K | (m) |
| 2019-06-30 | (m) | $36.40M | $149.41M | (m) | $3.10M | $732.00K | (m) |
| 2019-03-31 | (m) | $48.96M | $116.44M | (m) | $8.02M | $629.00K | (m) |
| 2018-12-31 | (m) | $55.61M | $65.51M | (m) | $5.50M | $678.00K | (m) |
| 2018-09-30 | (m) | $70.78M | $95.87M | (m) | $5.43M | $674.00K | (m) |
| 2018-06-30 | (m) | $62.16M | $98.59M | (m) | $5.32M | $299.00K | (m) |
| 2018-03-31 | (m) | $79.33M | $124.02M | (m) | $8.31M | $222.00K | (m) |
| 2017-12-31 | (m) | $67.43M | $113.92M | (m) | $7.76M | $171.00K | (m) |
| 2017-09-30 | (m) | $68.43M | $110.54M | (m) | $5.58M | $318.00K | (m) |
| 2017-06-30 | (m) | $53.47M | $144.34M | (m) | $3.34M | $299.00K | (m) |
| 2017-03-31 | (m) | $52.80M | $134.04M | (m) | $1.37M | $204.00K | (m) |
| 2016-12-31 | (m) | $56.56M | $88.29M | (m) | $1.83M | $203.00K | (m) |
| 2016-09-30 | (m) | $38.59M | $82.54M | (m) | $5.01M | $123.00K | (m) |
| 2016-06-30 | (m) | $14.34M | $71.34M | (m) | $967.00K | $100.00K | (m) |
| 2016-03-31 | (m) | $10.84M | $81.42M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $10.58M | $98.18M | $0.00 | (m) | (m) | (m) |
| 2015-09-30 | (m) | $8.45M | $25.56M | $39.95M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $5.00M | $41.04M | $20.00M | (m) | (m) | (m) |
| 2015-03-31 | (m) | $5.93M | $48.93M | $20.00M | (m) | (m) | (m) |
| 2014-12-31 | (m) | $4.08M | $49.76M | $20.00M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $3.56M | $71.59M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $3.44M | $75.80M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $4.33M | $79.98M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $11.21M | $99.52M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $9.64M | $106.27M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $8.95M | $67.89M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $6.17M | $44.05M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $5.13M | $40.20M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $4.46M | $47.48M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $3.93M | $38.21M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $3.84M | $17.73M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $3.49M | $23.16M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $3.69M | $26.71M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | $29.65M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $9.27M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $1.56M | $14.86M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $15.78M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $1.51M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $7.00K | (m) | (m) | (m) | (m) |
| 2006-06-27 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |